| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| AMGN - Amgen Inc | BUY | 331 @ USD 345.42 | USD 114,334 | The ETF bought 331 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 345.42 compared to the previous average buy price of 298.446. This is 15.7% higher than average price of previous purchases of AMGN. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 237 @ USD 463.13 | USD 109,762 | The ETF bought 237 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 463.13 compared to the previous average buy price of 437.406. This is 5.9% higher than average price of previous purchases of VRTX. |
| GILD - Guild Esports Plc | BUY | 826 @ USD 125 | USD 103,250 | The ETF bought 826 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 125 compared to the previous average buy price of 115.069. This is 8.6% higher than average price of previous purchases of GILD. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 111 @ USD 723.67 | USD 80,327 | The ETF bought 111 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 723.67 compared to the previous average buy price of 643.144. This is 12.5% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 151 @ USD 473.29 | USD 71,467 | The ETF bought 151 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 473.29 compared to the previous average buy price of 377.661. This is 25.3% higher than average price of previous purchases of ALNY. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 14,742 @ USD 3.73 | USD 54,988 | The ETF bought 14742 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 3.73 compared to the previous average buy price of 1.65809. This is 125.0% higher than average price of previous purchases of IRWD. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 717 @ USD 74.55 | USD 53,452 | The ETF bought 717 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 74.55 compared to the previous average buy price of 48.2394. This is 54.5% higher than average price of previous purchases of APGE. |
| AZN - AstraZeneca PLC | BUY | 587 @ USD 90.85 | USD 53,329 | The ETF bought 587 new shares of AZN (AstraZeneca PLC). The shares were bought for an average price of 90.85 compared to the previous average buy price of 77.3058. This is 17.5% higher than average price of previous purchases of AZN. |
| ILMN - Illumina Inc | BUY | 414 @ USD 127.95 | USD 52,971 | The ETF bought 414 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 127.95 compared to the previous average buy price of 102.058. This is 25.4% higher than average price of previous purchases of ILMN. |
| INSM - Insmed Inc | BUY | 250 @ USD 206.78 | USD 51,695 | The ETF bought 250 new shares of INSM (Insmed Inc). The shares were bought for an average price of 206.78 compared to the previous average buy price of 132.92. This is 55.6% higher than average price of previous purchases of INSM. |
| RNA - Avidity Biosciences Inc | BUY | 720 @ USD 71.58 | USD 51,538 | The ETF bought 720 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 71.58 compared to the previous average buy price of 43.2299. This is 65.6% higher than average price of previous purchases of RNA. |
| EXEL - Exelixis Inc | BUY | 1,169 @ USD 44.01 | USD 51,448 | The ETF bought 1169 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 44.01 compared to the previous average buy price of 41.3969. This is 6.3% higher than average price of previous purchases of EXEL. |
| ROIV - Roivant Sciences Ltd | BUY | 2,480 @ USD 20.7 | USD 51,336 | The ETF bought 2480 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 20.7 compared to the previous average buy price of 14.3598. This is 44.2% higher than average price of previous purchases of ROIV. |
| BIIB - Biogen Inc | BUY | 284 @ USD 180.75 | USD 51,333 | The ETF bought 284 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 180.75 compared to the previous average buy price of 145.296. This is 24.4% higher than average price of previous purchases of BIIB. |
| RPRX - Royalty Pharma Plc | BUY | 1,290 @ USD 39.6 | USD 51,084 | The ETF bought 1290 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 39.6 compared to the previous average buy price of 36.2999. This is 9.1% higher than average price of previous purchases of RPRX. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 1,684 @ USD 29.96 | USD 50,453 | The ETF bought 1684 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 29.96 compared to the previous average buy price of 18.5308. This is 61.7% higher than average price of previous purchases of ARQT. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 87 @ USD 579.89 | USD 50,450 | The ETF bought 87 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 579.89 compared to the previous average buy price of 388.535. This is 49.3% higher than average price of previous purchases of MDGL. |
| COGT - Cogent Biosciences Inc | BUY | 1,283 @ USD 39.16 | USD 50,242 | The ETF bought 1283 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 39.16 compared to the previous average buy price of 15.5564. This is 151.7% higher than average price of previous purchases of COGT. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 923 @ USD 54.31 | USD 50,128 | The ETF bought 923 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 54.31 compared to the previous average buy price of 57.5635. This is -5.7% lower than average price of previous purchases of BMRN. |
| MRNA - Moderna Inc | BUY | 1,986 @ USD 25.18 | USD 50,007 | The ETF bought 1986 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 25.18 compared to the previous average buy price of 28.2623. This is -10.9% lower than average price of previous purchases of MRNA. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 1,822 @ USD 27.25 | USD 49,650 | The ETF bought 1822 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 27.25 compared to the previous average buy price of 8.30926. This is 227.9% higher than average price of previous purchases of OLMA. |
| ASND - Ascendis Pharma AS | BUY | 243 @ USD 200.5 | USD 48,722 | The ETF bought 243 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 200.5 compared to the previous average buy price of 183.275. This is 9.4% higher than average price of previous purchases of ASND. |
| JANX - Janux Therapeutics Inc | BUY | 1,485 @ USD 17.11 | USD 25,408 | The ETF bought 1485 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 17.11 compared to the previous average buy price of 28.0942. This is -39.1% lower than average price of previous purchases of JANX. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| ABCL - Abcellera Biologics Inc | HOLD | 0 @ USD 3.49 | USD 0 | The current share valuation price of ABCL based on adjusted close was USD 3.49. The average price that ABCL shares were previous bought at was USD 3.84864. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in ABCL has increased by USD 6,236 compared to the previous valuation of Abcellera Biologics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ABUS - Arbutus Biopharma Corp | HOLD | 0 @ USD 4.43 | USD 0 | The current share valuation price of ABUS based on adjusted close was USD 4.43. The average price that ABUS shares were previous bought at was USD 3.77126. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in ABUS has increased by USD 35,326 compared to the previous valuation of Arbutus Biopharma Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ACAD - ACADIA Pharmaceuticals Inc | HOLD | 0 @ USD 25.88 | USD 0 | The current share valuation price of ACAD based on adjusted close was USD 25.88. The average price that ACAD shares were previous bought at was USD 21.5349. The current market price is 20.2% higher than average price they were purchased at. The value of the holding in ACAD has increased by USD 53,563 compared to the previous valuation of ACADIA Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ACIU - AC Immune Ltd | HOLD | 0 @ USD 2.84999 | USD 0 | The current share valuation price of ACIU based on adjusted close was USD 2.84999. The average price that ACIU shares were previous bought at was USD 2.5222. The current market price is 13.0% higher than average price they were purchased at. The value of the holding in ACIU has increased by USD 5,578 compared to the previous valuation of AC Immune Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ACLX - Arcellx Inc | HOLD | 0 @ USD 72.94 | USD 0 | The current share valuation price of ACLX based on adjusted close was USD 72.94. The average price that ACLX shares were previous bought at was USD 72.6395. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in ACLX has increased by USD 160,670 compared to the previous valuation of Arcellx Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ADMA - ADMA Biologics Inc | HOLD | 0 @ USD 19.72 | USD 0 | The current share valuation price of ADMA based on adjusted close was USD 19.72. The average price that ADMA shares were previous bought at was USD 17.5205. The current market price is 12.6% higher than average price they were purchased at. The value of the holding in ADMA has increased by USD 79,120 compared to the previous valuation of ADMA Biologics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ADPT - Adaptive Biotechnologies Corp | HOLD | 0 @ USD 17.13 | USD 0 | The current share valuation price of ADPT based on adjusted close was USD 17.13. The average price that ADPT shares were previous bought at was USD 12.9389. The current market price is 32.4% higher than average price they were purchased at. The value of the holding in ADPT has fallen by USD 165,025 compared to the previous valuation of Adaptive Biotechnologies Corp |
| AGIO - Agios Pharm | HOLD | 0 @ USD 27.49 | USD 0 | The current share valuation price of AGIO based on adjusted close was USD 27.49. The average price that AGIO shares were previous bought at was USD 35.2019. The current market price is -21.9% lower than average price they were purchased at. The value of the holding in AGIO has increased by USD 20,578 compared to the previous valuation of Agios Pharm however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AKRO - Akero Therapeutics Inc | HOLD | 0 @ USD 54.69 | USD 0 | The current share valuation price of AKRO based on adjusted close was USD 54.69. The average price that AKRO shares were previous bought at was USD 50.0906. The current market price is 9.2% higher than average price they were purchased at. The value of the holding in AKRO has increased by USD 11,246 compared to the previous valuation of Akero Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ALEC - Alector Inc | HOLD | 0 @ USD 1.14001 | USD 0 | The current share valuation price of ALEC based on adjusted close was USD 1.14001. The average price that ALEC shares were previous bought at was USD 1.78185. The current market price is -36.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of Alector Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ALKS - Alkermes Plc | HOLD | 0 @ USD 29.53 | USD 0 | The current share valuation price of ALKS based on adjusted close was USD 29.53. The average price that ALKS shares were previous bought at was USD 30.1965. The current market price is -2.2% lower than average price they were purchased at. The value of the holding in ALKS has increased by USD 64,860 compared to the previous valuation of Alkermes Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ALLO - Allogene Therapeutics Inc | HOLD | 0 @ USD 1.52 | USD 0 | The current share valuation price of ALLO based on adjusted close was USD 1.52. The average price that ALLO shares were previous bought at was USD 1.33646. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in ALLO has increased by USD 27,533 compared to the previous valuation of Allogene Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ALT - Altitude Group Plc | HOLD | 0 @ USD 5.11 | USD 0 | The current share valuation price of ALT based on adjusted close was USD 5.11. The average price that ALT shares were previous bought at was USD 5.18731. The current market price is -1.5% lower than average price they were purchased at. The value of the holding in ALT has increased by USD 20,761 compared to the previous valuation of Altitude Group Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AMLX - Amylyx Pharmaceuticals Inc | HOLD | 0 @ USD 14.21 | USD 0 | The current share valuation price of AMLX based on adjusted close was USD 14.21. The average price that AMLX shares were previous bought at was USD 7.9045. The current market price is 79.8% higher than average price they were purchased at. The value of the holding in AMLX has increased by USD 28,520 compared to the previous valuation of Amylyx Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AMPH - Amphastar P | HOLD | 0 @ USD 27.58 | USD 0 | The current share valuation price of AMPH based on adjusted close was USD 27.58. The average price that AMPH shares were previous bought at was USD 25.8062. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in AMPH has increased by USD 29,396 compared to the previous valuation of Amphastar P however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | HOLD | 0 @ USD 12.18 | USD 0 | The current share valuation price of AMRX based on adjusted close was USD 12.18. The average price that AMRX shares were previous bought at was USD 9.38444. The current market price is 29.8% higher than average price they were purchased at. The value of the holding in AMRX has increased by USD 39,946 compared to the previous valuation of Amneal Pharmaceuticals, Inc. Class A Common Stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ANAB - AnaptysBio Inc | HOLD | 0 @ USD 43.76 | USD 0 | The current share valuation price of ANAB based on adjusted close was USD 43.76. The average price that ANAB shares were previous bought at was USD 26.7585. The current market price is 63.5% higher than average price they were purchased at. The value of the holding in ANAB has increased by USD 55,621 compared to the previous valuation of AnaptysBio Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ANIP - ANI Pharmaceuticals Inc | HOLD | 0 @ USD 82.67 | USD 0 | The current share valuation price of ANIP based on adjusted close was USD 82.67. The average price that ANIP shares were previous bought at was USD 74.417. The current market price is 11.1% higher than average price they were purchased at. The value of the holding in ANIP has increased by USD 8,294 compared to the previous valuation of ANI Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| APLS - Apellis Pharmaceuticals Inc | HOLD | 0 @ USD 21.25 | USD 0 | The current share valuation price of APLS based on adjusted close was USD 21.25. The average price that APLS shares were previous bought at was USD 20.9917. The current market price is 1.2% higher than average price they were purchased at. The value of the holding in APLS has increased by USD 52,637 compared to the previous valuation of Apellis Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARCT - Arcturus Therapeutics Holdings Inc | HOLD | 0 @ USD 6.59 | USD 0 | The current share valuation price of ARCT based on adjusted close was USD 6.59. The average price that ARCT shares were previous bought at was USD 13.2151. The current market price is -50.1% lower than average price they were purchased at. The value of the holding in ARCT has increased by USD 6,764 compared to the previous valuation of Arcturus Therapeutics Holdings Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARDX - Ardelyx Inc | HOLD | 0 @ USD 5.77 | USD 0 | The current share valuation price of ARDX based on adjusted close was USD 5.77. The average price that ARDX shares were previous bought at was USD 4.80833. The current market price is 20.0% higher than average price they were purchased at. The value of the holding in ARDX has increased by USD 38,556 compared to the previous valuation of Ardelyx Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARGX - argenx NV ADR | HOLD | 0 @ USD 921.8 | USD 0 | The current share valuation price of ARGX based on adjusted close was USD 921.8. The average price that ARGX shares were previous bought at was USD 690.998. The current market price is 33.4% higher than average price they were purchased at. The value of the holding in ARGX has increased by USD 138,318 compared to the previous valuation of argenx NV ADR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARVN - Arvinas Inc | HOLD | 0 @ USD 12.67 | USD 0 | The current share valuation price of ARVN based on adjusted close was USD 12.67. The average price that ARVN shares were previous bought at was USD 9.27344. The current market price is 36.6% higher than average price they were purchased at. The value of the holding in ARVN has increased by USD 50,400 compared to the previous valuation of Arvinas Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARWR - Arrowhead Pharmaceuticals Inc | HOLD | 0 @ USD 65.075 | USD 0 | The current share valuation price of ARWR based on adjusted close was USD 65.075. The average price that ARWR shares were previous bought at was USD 25.9837. The current market price is 150.4% higher than average price they were purchased at. The value of the holding in ARWR has increased by USD 691,360 compared to the previous valuation of Arrowhead Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AUPH - Aurinia Pharmaceuticals Inc | HOLD | 0 @ USD 14.91 | USD 0 | The current share valuation price of AUPH based on adjusted close was USD 14.91. The average price that AUPH shares were previous bought at was USD 10.467. The current market price is 42.4% higher than average price they were purchased at. The value of the holding in AUPH has fallen by USD 91,501 compared to the previous valuation of Aurinia Pharmaceuticals Inc |
| AUTL - Autolus Therapeutics Ltd | HOLD | 0 @ USD 1.48 | USD 0 | The current share valuation price of AUTL based on adjusted close was USD 1.48. The average price that AUTL shares were previous bought at was USD 1.7457. The current market price is -15.2% lower than average price they were purchased at. The value of the holding in AUTL has increased by USD 21,236 compared to the previous valuation of Autolus Therapeutics Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AVDL - Avadel Pharmaceuticals PLC | HOLD | 0 @ USD 21.36 | USD 0 | The current share valuation price of AVDL based on adjusted close was USD 21.36. The average price that AVDL shares were previous bought at was USD 12.8833. The current market price is 65.8% higher than average price they were purchased at. The value of the holding in AVDL has increased by USD 675 compared to the previous valuation of Avadel Pharmaceuticals PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AVIR - Atea Pharmaceuticals Inc | HOLD | 0 @ USD 3.09 | USD 0 | The current share valuation price of AVIR based on adjusted close was USD 3.09. The average price that AVIR shares were previous bought at was USD 3.25973. The current market price is -5.2% lower than average price they were purchased at. The value of the holding in AVIR has increased by USD 5,265 compared to the previous valuation of Atea Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AVXL - Anavex Life Sciences Corp | HOLD | 0 @ USD 4.57 | USD 0 | The current share valuation price of AVXL based on adjusted close was USD 4.57. The average price that AVXL shares were previous bought at was USD 8.44632. The current market price is -45.9% lower than average price they were purchased at. The value of the holding in AVXL has increased by USD 53,942 compared to the previous valuation of Anavex Life Sciences Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AXSM - Axsome Therapeutics Inc | HOLD | 0 @ USD 147.81 | USD 0 | The current share valuation price of AXSM based on adjusted close was USD 147.81. The average price that AXSM shares were previous bought at was USD 120.425. The current market price is 22.7% higher than average price they were purchased at. The value of the holding in AXSM has increased by USD 199,856 compared to the previous valuation of Axsome Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BBIO - BridgeBio Pharma Inc | HOLD | 0 @ USD 74.15 | USD 0 | The current share valuation price of BBIO based on adjusted close was USD 74.15. The average price that BBIO shares were previous bought at was USD 49.0619. The current market price is 51.1% higher than average price they were purchased at. The value of the holding in BBIO has increased by USD 361,555 compared to the previous valuation of BridgeBio Pharma Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BCRX - BioCryst Pharmaceuticals Inc | HOLD | 0 @ USD 7.85 | USD 0 | The current share valuation price of BCRX based on adjusted close was USD 7.85. The average price that BCRX shares were previous bought at was USD 8.1012. The current market price is -3.1% lower than average price they were purchased at. The value of the holding in BCRX has increased by USD 100,716 compared to the previous valuation of BioCryst Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BCYC - Bicycle Therapeutics Ltd | HOLD | 0 @ USD 7.14 | USD 0 | The current share valuation price of BCYC based on adjusted close was USD 7.14. The average price that BCYC shares were previous bought at was USD 8.26933. The current market price is -13.7% lower than average price they were purchased at. The value of the holding in BCYC has increased by USD 8,924 compared to the previous valuation of Bicycle Therapeutics Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BEAM - Beam Therapeutics Inc | HOLD | 0 @ USD 26.74 | USD 0 | The current share valuation price of BEAM based on adjusted close was USD 26.74. The average price that BEAM shares were previous bought at was USD 20.9877. The current market price is 27.4% higher than average price they were purchased at. The value of the holding in BEAM has increased by USD 236,742 compared to the previous valuation of Beam Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BMEA - Biomea Fusion Inc | HOLD | 0 @ USD 1.05001 | USD 0 | The current share valuation price of BMEA based on adjusted close was USD 1.05001. The average price that BMEA shares were previous bought at was USD 1.57312. The current market price is -33.3% lower than average price they were purchased at. The value of the holding in BMEA has increased by USD 4,486 compared to the previous valuation of Biomea Fusion Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BNTX - BioNTech SE | HOLD | 0 @ USD 96.73 | USD 0 | The current share valuation price of BNTX based on adjusted close was USD 96.73. The average price that BNTX shares were previous bought at was USD 104.021. The current market price is -7.0% lower than average price they were purchased at. The value of the holding in BNTX has increased by USD 43,644 compared to the previous valuation of BioNTech SE however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CGEM - Cullinan Oncology LLC | HOLD | 0 @ USD 10.5 | USD 0 | The current share valuation price of CGEM based on adjusted close was USD 10.5. The average price that CGEM shares were previous bought at was USD 8.31013. The current market price is 26.4% higher than average price they were purchased at. The value of the holding in CGEM has increased by USD 12,775 compared to the previous valuation of Cullinan Oncology LLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CGON - CG Oncology, Inc. Common stock | HOLD | 0 @ USD 42.61 | USD 0 | The current share valuation price of CGON based on adjusted close was USD 42.61. The average price that CGON shares were previous bought at was USD 31.9844. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in CGON has increased by USD 66,733 compared to the previous valuation of CG Oncology, Inc. Common stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CNTA - Centessa Pharmaceuticals PLC ADR | HOLD | 0 @ USD 29.07 | USD 0 | The current share valuation price of CNTA based on adjusted close was USD 29.07. The average price that CNTA shares were previous bought at was USD 18.2451. The current market price is 59.3% higher than average price they were purchased at. The value of the holding in CNTA has increased by USD 37,301 compared to the previous valuation of Centessa Pharmaceuticals PLC ADR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| COLL - Collegium Pharmaceutical Inc | HOLD | 0 @ USD 47.85 | USD 0 | The current share valuation price of COLL based on adjusted close was USD 47.85. The average price that COLL shares were previous bought at was USD 34.2795. The current market price is 39.6% higher than average price they were purchased at. The value of the holding in COLL has increased by USD 7,442 compared to the previous valuation of Collegium Pharmaceutical Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CRNX - Crinetics Pharmaceuticals Inc | HOLD | 0 @ USD 46.98 | USD 0 | The current share valuation price of CRNX based on adjusted close was USD 46.98. The average price that CRNX shares were previous bought at was USD 36.66. The current market price is 28.2% higher than average price they were purchased at. The value of the holding in CRNX has increased by USD 130,436 compared to the previous valuation of Crinetics Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CRSP - Crispr Therapeutics AG | HOLD | 0 @ USD 55.99 | USD 0 | The current share valuation price of CRSP based on adjusted close was USD 55.99. The average price that CRSP shares were previous bought at was USD 52.4024. The current market price is 6.8% higher than average price they were purchased at. The value of the holding in CRSP has increased by USD 280,648 compared to the previous valuation of Crispr Therapeutics AG however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CSTL - Castle Biosciences Inc | HOLD | 0 @ USD 39.41 | USD 0 | The current share valuation price of CSTL based on adjusted close was USD 39.41. The average price that CSTL shares were previous bought at was USD 24.764. The current market price is 59.1% higher than average price they were purchased at. The value of the holding in CSTL has increased by USD 6,270 compared to the previous valuation of Castle Biosciences Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| CYTK - Cytokinetics Inc | HOLD | 0 @ USD 64.66 | USD 0 | The current share valuation price of CYTK based on adjusted close was USD 64.66. The average price that CYTK shares were previous bought at was USD 46.9185. The current market price is 37.8% higher than average price they were purchased at. The value of the holding in CYTK has increased by USD 96,260 compared to the previous valuation of Cytokinetics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DAWN - Day One Biopharmaceuticals Inc | HOLD | 0 @ USD 8.30999 | USD 0 | The current share valuation price of DAWN based on adjusted close was USD 8.30999. The average price that DAWN shares were previous bought at was USD 7.66426. The current market price is 8.4% higher than average price they were purchased at. The value of the holding in DAWN has fallen by USD 8,488 compared to the previous valuation of Day One Biopharmaceuticals Inc |
| DNLI - Denali Therapeutics Inc | HOLD | 0 @ USD 19 | USD 0 | The current share valuation price of DNLI based on adjusted close was USD 19. The average price that DNLI shares were previous bought at was USD 15.7017. The current market price is 21.0% higher than average price they were purchased at. The value of the holding in DNLI has increased by USD 117,822 compared to the previous valuation of Denali Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DVAX - Dynavax Technologies Corporation | HOLD | 0 @ USD 10.97 | USD 0 | The current share valuation price of DVAX based on adjusted close was USD 10.97. The average price that DVAX shares were previous bought at was USD 10.5828. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in DVAX has increased by USD 7,340 compared to the previous valuation of Dynavax Technologies Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DYN - Dyne Therapeutics Inc | HOLD | 0 @ USD 20.09 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.09. The average price that DYN shares were previous bought at was USD 14.1939. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 10,043 compared to the previous valuation of Dyne Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | HOLD | 0 @ USD 20.09 | USD 0 | The current share valuation price of DYN based on adjusted close was USD 20.09. The average price that DYN shares were previous bought at was USD 14.1939. The current market price is 41.5% higher than average price they were purchased at. The value of the holding in DYN has increased by USD 10,043 compared to the previous valuation of DYNAGREEN EN.PR.GR.H YC 1 however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| EDIT - Editas Medicine Inc | HOLD | 0 @ USD 2.365 | USD 0 | The current share valuation price of EDIT based on adjusted close was USD 2.365. The average price that EDIT shares were previous bought at was USD 2.6439. The current market price is -10.5% lower than average price they were purchased at. The value of the holding in EDIT has increased by USD 17,065 compared to the previous valuation of Editas Medicine Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ELVN - Enliven Therapeutics Inc. | HOLD | 0 @ USD 21 | USD 0 | The current share valuation price of ELVN based on adjusted close was USD 21. The average price that ELVN shares were previous bought at was USD 20.9313. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in ELVN has increased by USD 18,101 compared to the previous valuation of Enliven Therapeutics Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| EOLS - Evolus Inc | HOLD | 0 @ USD 6.75 | USD 0 | The current share valuation price of EOLS based on adjusted close was USD 6.75. The average price that EOLS shares were previous bought at was USD 8.77445. The current market price is -23.1% lower than average price they were purchased at. The value of the holding in EOLS has increased by USD 11,233 compared to the previous valuation of Evolus Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ERAS - Erasca Inc | HOLD | 0 @ USD 3.29 | USD 0 | The current share valuation price of ERAS based on adjusted close was USD 3.29. The average price that ERAS shares were previous bought at was USD 1.88621. The current market price is 74.4% higher than average price they were purchased at. The value of the holding in ERAS has increased by USD 84,461 compared to the previous valuation of Erasca Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| EWTX - Edgewise Therapeutics Inc | HOLD | 0 @ USD 23.32 | USD 0 | The current share valuation price of EWTX based on adjusted close was USD 23.32. The average price that EWTX shares were previous bought at was USD 17.1071. The current market price is 36.3% higher than average price they were purchased at. The value of the holding in EWTX has increased by USD 24,886 compared to the previous valuation of Edgewise Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| EYPT - Eyepoint Pharmaceuticals Inc | HOLD | 0 @ USD 14.52 | USD 0 | The current share valuation price of EYPT based on adjusted close was USD 14.52. The average price that EYPT shares were previous bought at was USD 9.50931. The current market price is 52.7% higher than average price they were purchased at. The value of the holding in EYPT has increased by USD 39,802 compared to the previous valuation of Eyepoint Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| FATE - Fate Therapeutics Inc | HOLD | 0 @ USD 1.07999 | USD 0 | The current share valuation price of FATE based on adjusted close was USD 1.07999. The average price that FATE shares were previous bought at was USD 1.15543. The current market price is -6.5% lower than average price they were purchased at. The value of the holding in FATE has increased by USD 5,701 compared to the previous valuation of Fate Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| FDMT - 4D Molecular Therapeutics Inc | HOLD | 0 @ USD 10.7 | USD 0 | The current share valuation price of FDMT based on adjusted close was USD 10.7. The average price that FDMT shares were previous bought at was USD 7.3079. The current market price is 46.4% higher than average price they were purchased at. The value of the holding in FDMT has increased by USD 19,873 compared to the previous valuation of 4D Molecular Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| FOLD - Amicus Therapeutics Inc | HOLD | 0 @ USD 9.78 | USD 0 | The current share valuation price of FOLD based on adjusted close was USD 9.78. The average price that FOLD shares were previous bought at was USD 7.79436. The current market price is 25.5% higher than average price they were purchased at. The value of the holding in FOLD has increased by USD 10,706 compared to the previous valuation of Amicus Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| FTRE - Fortrea Holdings Inc. | HOLD | 0 @ USD 14.58 | USD 0 | The current share valuation price of FTRE based on adjusted close was USD 14.58. The average price that FTRE shares were previous bought at was USD 7.69173. The current market price is 89.6% higher than average price they were purchased at. The value of the holding in FTRE has increased by USD 115,599 compared to the previous valuation of Fortrea Holdings Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GERN - Geron Corporation | HOLD | 0 @ USD 1.27 | USD 0 | The current share valuation price of GERN based on adjusted close was USD 1.27. The average price that GERN shares were previous bought at was USD 1.46453. The current market price is -13.3% lower than average price they were purchased at. The value of the holding in GERN has increased by USD 17,589 compared to the previous valuation of Geron Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GH - Guardant Health Inc | HOLD | 0 @ USD 105.96 | USD 0 | The current share valuation price of GH based on adjusted close was USD 105.96. The average price that GH shares were previous bought at was USD 63.7918. The current market price is 66.1% higher than average price they were purchased at. The value of the holding in GH has increased by USD 183,533 compared to the previous valuation of Guardant Health Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GLPG - Galapagos NV ADR | HOLD | 0 @ USD 31.77 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.77. The average price that GLPG shares were previous bought at was USD 29.4105. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 4,422 compared to the previous valuation of Galapagos NV ADR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GLPG - Galapagos N.V. | HOLD | 0 @ USD 31.77 | USD 0 | The current share valuation price of GLPG based on adjusted close was USD 31.77. The average price that GLPG shares were previous bought at was USD 29.4105. The current market price is 8.0% higher than average price they were purchased at. The value of the holding in GLPG has increased by USD 4,422 compared to the previous valuation of Galapagos N.V. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GMAB - Genmab AS | HOLD | 0 @ USD 31.68 | USD 0 | The current share valuation price of GMAB based on adjusted close was USD 31.68. The average price that GMAB shares were previous bought at was USD 24.817. The current market price is 27.7% higher than average price they were purchased at. The value of the holding in GMAB has fallen by USD 874 compared to the previous valuation of Genmab AS |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | HOLD | 0 @ USD 31.62 | USD 0 | The current share valuation price of GPCR based on adjusted close was USD 31.62. The average price that GPCR shares were previous bought at was USD 25.1239. The current market price is 25.9% higher than average price they were purchased at. The value of the holding in GPCR has fallen by USD 20,686 compared to the previous valuation of Structure Therapeutics Inc. American Depositary Shares |
| GRAL - GRAIL, LLC | HOLD | 0 @ USD 101.19 | USD 0 | The current share valuation price of GRAL based on adjusted close was USD 101.19. The average price that GRAL shares were previous bought at was USD 60.1271. The current market price is 68.3% higher than average price they were purchased at. The value of the holding in GRAL has increased by USD 97,040 compared to the previous valuation of GRAIL, LLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GRFS - Grifols SA ADR | HOLD | 0 @ USD 8.78 | USD 0 | The current share valuation price of GRFS based on adjusted close was USD 8.78. The average price that GRFS shares were previous bought at was USD 9.21178. The current market price is -4.7% lower than average price they were purchased at. The value of the holding in GRFS has increased by USD 22,923 compared to the previous valuation of Grifols SA ADR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HALO - Halozyme Therapeutics Inc | HOLD | 0 @ USD 64.66 | USD 0 | The current share valuation price of HALO based on adjusted close was USD 64.66. The average price that HALO shares were previous bought at was USD 61.5271. The current market price is 5.1% higher than average price they were purchased at. The value of the holding in HALO has fallen by USD 153,850 compared to the previous valuation of Halozyme Therapeutics Inc |
| HCM - HUTCHMED China Ltd | HOLD | 0 @ USD 14.26 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.26. The average price that HCM shares were previous bought at was USD 15.2325. The current market price is -6.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of HUTCHMED China Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HCM - Hitachi Construction Machinery Co. Ltd | HOLD | 0 @ USD 14.26 | USD 0 | The current share valuation price of HCM based on adjusted close was USD 14.26. The average price that HCM shares were previous bought at was USD 15.2325. The current market price is -6.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Hitachi Construction Machinery Co. Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HRMY - Harmony Biosciences Holdings | HOLD | 0 @ USD 37 | USD 0 | The current share valuation price of HRMY based on adjusted close was USD 37. The average price that HRMY shares were previous bought at was USD 32.3847. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in HRMY has increased by USD 39,565 compared to the previous valuation of Harmony Biosciences Holdings however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HROW - Harrow Health Inc | HOLD | 0 @ USD 44.52 | USD 0 | The current share valuation price of HROW based on adjusted close was USD 44.52. The average price that HROW shares were previous bought at was USD 34.5965. The current market price is 28.7% higher than average price they were purchased at. The value of the holding in HROW has increased by USD 111,752 compared to the previous valuation of Harrow Health Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HUMA - Humacyte Inc | HOLD | 0 @ USD 1.29 | USD 0 | The current share valuation price of HUMA based on adjusted close was USD 1.29. The average price that HUMA shares were previous bought at was USD 2.05909. The current market price is -37.4% lower than average price they were purchased at. The value of the holding in HUMA has increased by USD 3,407 compared to the previous valuation of Humacyte Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IBRX - Immunitybio Inc | HOLD | 0 @ USD 2.2 | USD 0 | The current share valuation price of IBRX based on adjusted close was USD 2.2. The average price that IBRX shares were previous bought at was USD 2.66634. The current market price is -17.5% lower than average price they were purchased at. The value of the holding in IBRX has increased by USD 73,285 compared to the previous valuation of Immunitybio Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IDYA - Ideaya Biosciences Inc | HOLD | 0 @ USD 34.34 | USD 0 | The current share valuation price of IDYA based on adjusted close was USD 34.34. The average price that IDYA shares were previous bought at was USD 25.1666. The current market price is 36.5% higher than average price they were purchased at. The value of the holding in IDYA has increased by USD 40,382 compared to the previous valuation of Ideaya Biosciences Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IMCR - Immunocore Holdings Ltd | HOLD | 0 @ USD 37.88 | USD 0 | The current share valuation price of IMCR based on adjusted close was USD 37.88. The average price that IMCR shares were previous bought at was USD 33.6315. The current market price is 12.6% higher than average price they were purchased at. The value of the holding in IMCR has increased by USD 48,881 compared to the previous valuation of Immunocore Holdings Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IMVT - Immunovant Inc | HOLD | 0 @ USD 22.71 | USD 0 | The current share valuation price of IMVT based on adjusted close was USD 22.71. The average price that IMVT shares were previous bought at was USD 18.7873. The current market price is 20.9% higher than average price they were purchased at. The value of the holding in IMVT has increased by USD 85,076 compared to the previous valuation of Immunovant Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 101.5 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 101.5. The average price that INCY shares were previous bought at was USD 79.0892. The current market price is 28.3% higher than average price they were purchased at. The value of the holding in INCY has increased by USD 8,225 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| INVA - Innoviva Inc | HOLD | 0 @ USD 20.86 | USD 0 | The current share valuation price of INVA based on adjusted close was USD 20.86. The average price that INVA shares were previous bought at was USD 19.3903. The current market price is 7.6% higher than average price they were purchased at. The value of the holding in INVA has fallen by USD 5,227 compared to the previous valuation of Innoviva Inc |
| IONS - Ionis Pharmaceuticals Inc | HOLD | 0 @ USD 81.84 | USD 0 | The current share valuation price of IONS based on adjusted close was USD 81.84. The average price that IONS shares were previous bought at was USD 53.7989. The current market price is 52.1% higher than average price they were purchased at. The value of the holding in IONS has increased by USD 59,405 compared to the previous valuation of Ionis Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IOVA - Iovance Biotherapeutics Inc | HOLD | 0 @ USD 2.21 | USD 0 | The current share valuation price of IOVA based on adjusted close was USD 2.21. The average price that IOVA shares were previous bought at was USD 2.41537. The current market price is -8.5% lower than average price they were purchased at. The value of the holding in IOVA has increased by USD 18,517 compared to the previous valuation of Iovance Biotherapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IRON - Ironveld Plc | HOLD | 0 @ USD 92.38 | USD 0 | The current share valuation price of IRON based on adjusted close was USD 92.38. The average price that IRON shares were previous bought at was USD 63.5477. The current market price is 45.4% higher than average price they were purchased at. The value of the holding in IRON has increased by USD 65,351 compared to the previous valuation of Ironveld Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| JAZZ - Jazz Pharmaceuticals PLC | HOLD | 0 @ USD 167.1 | USD 0 | The current share valuation price of JAZZ based on adjusted close was USD 167.1. The average price that JAZZ shares were previous bought at was USD 131.002. The current market price is 27.6% higher than average price they were purchased at. The value of the holding in JAZZ has increased by USD 16,558 compared to the previous valuation of Jazz Pharmaceuticals PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KALV - Kalvista Pharmaceuticals Inc | HOLD | 0 @ USD 14.66 | USD 0 | The current share valuation price of KALV based on adjusted close was USD 14.66. The average price that KALV shares were previous bought at was USD 12.5178. The current market price is 17.1% higher than average price they were purchased at. The value of the holding in KALV has increased by USD 38,966 compared to the previous valuation of Kalvista Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KNSA - Kiniksa Pharmaceuticals Ltd | HOLD | 0 @ USD 40.59 | USD 0 | The current share valuation price of KNSA based on adjusted close was USD 40.59. The average price that KNSA shares were previous bought at was USD 31.8668. The current market price is 27.4% higher than average price they were purchased at. The value of the holding in KNSA has increased by USD 15,931 compared to the previous valuation of Kiniksa Pharmaceuticals Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KROS - Keros Therapeutics Inc | HOLD | 0 @ USD 18.1 | USD 0 | The current share valuation price of KROS based on adjusted close was USD 18.1. The average price that KROS shares were previous bought at was USD 14.3335. The current market price is 26.3% higher than average price they were purchased at. The value of the holding in KROS has increased by USD 35,336 compared to the previous valuation of Keros Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KRYS - Krystal Biotech Inc | HOLD | 0 @ USD 217.46 | USD 0 | The current share valuation price of KRYS based on adjusted close was USD 217.46. The average price that KRYS shares were previous bought at was USD 170.264. The current market price is 27.7% higher than average price they were purchased at. The value of the holding in KRYS has increased by USD 48,703 compared to the previous valuation of Krystal Biotech Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KURA - Kura Oncology Inc | HOLD | 0 @ USD 11.97 | USD 0 | The current share valuation price of KURA based on adjusted close was USD 11.97. The average price that KURA shares were previous bought at was USD 7.93634. The current market price is 50.8% higher than average price they were purchased at. The value of the holding in KURA has increased by USD 52,852 compared to the previous valuation of Kura Oncology Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| KYMR - Kymera Therapeutics Inc | HOLD | 0 @ USD 65.99 | USD 0 | The current share valuation price of KYMR based on adjusted close was USD 65.99. The average price that KYMR shares were previous bought at was USD 49.68. The current market price is 32.8% higher than average price they were purchased at. The value of the holding in KYMR has increased by USD 86,506 compared to the previous valuation of Kymera Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| LEGN - Legend Biotech Corp | HOLD | 0 @ USD 27.75 | USD 0 | The current share valuation price of LEGN based on adjusted close was USD 27.75. The average price that LEGN shares were previous bought at was USD 33.3048. The current market price is -16.7% lower than average price they were purchased at. The value of the holding in LEGN has increased by USD 62,530 compared to the previous valuation of Legend Biotech Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| LGND - Ligand Pharmaceuticals Incorporated | HOLD | 0 @ USD 193.03 | USD 0 | The current share valuation price of LGND based on adjusted close was USD 193.03. The average price that LGND shares were previous bought at was USD 144.961. The current market price is 33.2% higher than average price they were purchased at. The value of the holding in LGND has fallen by USD 28,601 compared to the previous valuation of Ligand Pharmaceuticals Incorporated |
| LXRX - Lexicon Pharmaceuticals Inc | HOLD | 0 @ USD 1.4 | USD 0 | The current share valuation price of LXRX based on adjusted close was USD 1.4. The average price that LXRX shares were previous bought at was USD 1.12622. The current market price is 24.3% higher than average price they were purchased at. The value of the holding in LXRX has increased by USD 15,794 compared to the previous valuation of Lexicon Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| LYEL - Lyell Immunopharma Inc | HOLD | 0 @ USD 22.31 | USD 0 | The current share valuation price of LYEL based on adjusted close was USD 22.31. The average price that LYEL shares were previous bought at was USD 5.74894. The current market price is 288.1% higher than average price they were purchased at. The value of the holding in LYEL has increased by USD 20,068 compared to the previous valuation of Lyell Immunopharma Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MEDP - Medpace Holdings Inc | HOLD | 0 @ USD 576.49 | USD 0 | The current share valuation price of MEDP based on adjusted close was USD 576.49. The average price that MEDP shares were previous bought at was USD 429.863. The current market price is 34.1% higher than average price they were purchased at. The value of the holding in MEDP has fallen by USD 142,261 compared to the previous valuation of Medpace Holdings Inc |
| MGNX - MacroGenics Inc | HOLD | 0 @ USD 1.40001 | USD 0 | The current share valuation price of MGNX based on adjusted close was USD 1.40001. The average price that MGNX shares were previous bought at was USD 1.55233. The current market price is -9.8% lower than average price they were purchased at. The value of the holding in MGNX has fallen by USD 861 compared to the previous valuation of MacroGenics Inc |
| MGTX - MeiraGTx Holdings PLC | HOLD | 0 @ USD 8.11999 | USD 0 | The current share valuation price of MGTX based on adjusted close was USD 8.11999. The average price that MGTX shares were previous bought at was USD 7.28262. The current market price is 11.5% higher than average price they were purchased at. The value of the holding in MGTX has increased by USD 20,739 compared to the previous valuation of MeiraGTx Holdings PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MIRM - Mirum Pharmaceuticals Inc | HOLD | 0 @ USD 70.99 | USD 0 | The current share valuation price of MIRM based on adjusted close was USD 70.99. The average price that MIRM shares were previous bought at was USD 58.2291. The current market price is 21.9% higher than average price they were purchased at. The value of the holding in MIRM has increased by USD 39,302 compared to the previous valuation of Mirum Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | HOLD | 0 @ USD 39.2 | USD 0 | The current share valuation price of MLYS based on adjusted close was USD 39.2. The average price that MLYS shares were previous bought at was USD 22.7933. The current market price is 72.0% higher than average price they were purchased at. The value of the holding in MLYS has increased by USD 2,301 compared to the previous valuation of Mineralys Therapeutics, Inc. Common Stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MNKD - MannKind Corp | HOLD | 0 @ USD 5.59 | USD 0 | The current share valuation price of MNKD based on adjusted close was USD 5.59. The average price that MNKD shares were previous bought at was USD 4.84116. The current market price is 15.5% higher than average price they were purchased at. USD 0 compared to the previous valuation of MannKind Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MNMD - Mind Medicine Inc | HOLD | 0 @ USD 11.94 | USD 0 | The current share valuation price of MNMD based on adjusted close was USD 11.94. The average price that MNMD shares were previous bought at was USD 9.1767. The current market price is 30.1% higher than average price they were purchased at. The value of the holding in MNMD has fallen by USD 6,470 compared to the previous valuation of Mind Medicine Inc |
| MRSN - Mersana Therapeutics Inc | HOLD | 0 @ USD 27.8501 | USD 0 | The current share valuation price of MRSN based on adjusted close was USD 27.8501. The average price that MRSN shares were previous bought at was USD 1.00518. The current market price is 2,670.7% higher than average price they were purchased at. The value of the holding in MRSN has increased by USD 1,085 compared to the previous valuation of Mersana Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MRUS - Merus BV | HOLD | 0 @ USD 96.12 | USD 0 | The current share valuation price of MRUS based on adjusted close was USD 96.12. The average price that MRUS shares were previous bought at was USD 69.5043. The current market price is 38.3% higher than average price they were purchased at. The value of the holding in MRUS has increased by USD 6,897 compared to the previous valuation of Merus BV however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MRVI - Maravai Lifesciences Holdings Inc | HOLD | 0 @ USD 3.51 | USD 0 | The current share valuation price of MRVI based on adjusted close was USD 3.51. The average price that MRVI shares were previous bought at was USD 2.85219. The current market price is 23.1% higher than average price they were purchased at. The value of the holding in MRVI has increased by USD 7,618 compared to the previous valuation of Maravai Lifesciences Holdings Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MXCT - MaxCyte Inc | HOLD | 0 @ USD 1.52 | USD 0 | The current share valuation price of MXCT based on adjusted close was USD 1.52. The average price that MXCT shares were previous bought at was USD 2.06303. The current market price is -26.3% lower than average price they were purchased at. The value of the holding in MXCT has fallen by USD 3,733 compared to the previous valuation of MaxCyte Inc |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.96 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.96. The average price that NBIX shares were previous bought at was USD 132.895. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 36,224 compared to the previous valuation of Neurocrine Biosciences Inc |
| NRIX - Nurix Therapeutics Inc | HOLD | 0 @ USD 16.83 | USD 0 | The current share valuation price of NRIX based on adjusted close was USD 16.83. The average price that NRIX shares were previous bought at was USD 12.6654. The current market price is 32.9% higher than average price they were purchased at. The value of the holding in NRIX has increased by USD 26,836 compared to the previous valuation of Nurix Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NTLA - Intellia Therapeutics Inc | HOLD | 0 @ USD 9.06001 | USD 0 | The current share valuation price of NTLA based on adjusted close was USD 9.06001. The average price that NTLA shares were previous bought at was USD 11.6822. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in NTLA has increased by USD 72,571 compared to the previous valuation of Intellia Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NUVL - Nuvalent Inc | HOLD | 0 @ USD 106.9 | USD 0 | The current share valuation price of NUVL based on adjusted close was USD 106.9. The average price that NUVL shares were previous bought at was USD 86.3368. The current market price is 23.8% higher than average price they were purchased at. The value of the holding in NUVL has increased by USD 90,631 compared to the previous valuation of Nuvalent Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NVAX - Novavax Inc | HOLD | 0 @ USD 6.84 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.84. The average price that NVAX shares were previous bought at was USD 7.26893. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 27,113 compared to the previous valuation of Novavax Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NVAX - Hana Microelectronics Public Company Limited | HOLD | 0 @ USD 6.84 | USD 0 | The current share valuation price of NVAX based on adjusted close was USD 6.84. The average price that NVAX shares were previous bought at was USD 7.26893. The current market price is -5.9% lower than average price they were purchased at. The value of the holding in NVAX has increased by USD 27,113 compared to the previous valuation of Hana Microelectronics Public Company Limited however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NVCR - Novocure Ltd | HOLD | 0 @ USD 11.81 | USD 0 | The current share valuation price of NVCR based on adjusted close was USD 11.81. The average price that NVCR shares were previous bought at was USD 15.8688. The current market price is -25.6% lower than average price they were purchased at. The value of the holding in NVCR has increased by USD 69,178 compared to the previous valuation of Novocure Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| OABI - OmniAb Inc. | HOLD | 0 @ USD 1.88 | USD 0 | The current share valuation price of OABI based on adjusted close was USD 1.88. The average price that OABI shares were previous bought at was USD 1.868. The current market price is 0.6% higher than average price they were purchased at. The value of the holding in OABI has increased by USD 14,641 compared to the previous valuation of OmniAb Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| OCUL - Ocular Therapeutix Inc | HOLD | 0 @ USD 11.46 | USD 0 | The current share valuation price of OCUL based on adjusted close was USD 11.46. The average price that OCUL shares were previous bought at was USD 10.0242. The current market price is 14.3% higher than average price they were purchased at. The value of the holding in OCUL has increased by USD 25,382 compared to the previous valuation of Ocular Therapeutix Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| OKUR - OKUR | HOLD | 0 @ USD 2.62 | USD 0 | The current share valuation price of OKUR based on adjusted close was USD 2.62. The average price that OKUR shares were previous bought at was USD 5.8164. The current market price is -55.0% lower than average price they were purchased at. USD 0 compared to the previous valuation of OKUR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ORIC - Oric Pharmaceuticals Inc | HOLD | 0 @ USD 10.98 | USD 0 | The current share valuation price of ORIC based on adjusted close was USD 10.98. The average price that ORIC shares were previous bought at was USD 10.6625. The current market price is 3.0% higher than average price they were purchased at. The value of the holding in ORIC has increased by USD 22,277 compared to the previous valuation of Oric Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PACB - Pacific Biosciences of California | HOLD | 0 @ USD 2.43 | USD 0 | The current share valuation price of PACB based on adjusted close was USD 2.43. The average price that PACB shares were previous bought at was USD 1.64949. The current market price is 47.3% higher than average price they were purchased at. The value of the holding in PACB has increased by USD 24,266 compared to the previous valuation of Pacific Biosciences of California however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PAHC - Phibro Animal Health Corporation | HOLD | 0 @ USD 41.39 | USD 0 | The current share valuation price of PAHC based on adjusted close was USD 41.39. The average price that PAHC shares were previous bought at was USD 30.5676. The current market price is 35.4% higher than average price they were purchased at. The value of the holding in PAHC has increased by USD 9,925 compared to the previous valuation of Phibro Animal Health Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PCRX - Pacira BioSciences, Inc. | HOLD | 0 @ USD 24.19 | USD 0 | The current share valuation price of PCRX based on adjusted close was USD 24.19. The average price that PCRX shares were previous bought at was USD 23.8585. The current market price is 1.4% higher than average price they were purchased at. The value of the holding in PCRX has increased by USD 3,748 compared to the previous valuation of Pacira BioSciences, Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PCVX - Vaxcyte Inc | HOLD | 0 @ USD 47.7 | USD 0 | The current share valuation price of PCVX based on adjusted close was USD 47.7. The average price that PCVX shares were previous bought at was USD 45.2185. The current market price is 5.5% higher than average price they were purchased at. The value of the holding in PCVX has increased by USD 273,105 compared to the previous valuation of Vaxcyte Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PGEN - Precigen Inc | HOLD | 0 @ USD 3.57 | USD 0 | The current share valuation price of PGEN based on adjusted close was USD 3.57. The average price that PGEN shares were previous bought at was USD 2.58913. The current market price is 37.9% higher than average price they were purchased at. The value of the holding in PGEN has increased by USD 19,077 compared to the previous valuation of Precigen Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PHAT - Phathom Pharmaceuticals Inc | HOLD | 0 @ USD 14.67 | USD 0 | The current share valuation price of PHAT based on adjusted close was USD 14.67. The average price that PHAT shares were previous bought at was USD 10.0671. The current market price is 45.7% higher than average price they were purchased at. The value of the holding in PHAT has fallen by USD 3,524 compared to the previous valuation of Phathom Pharmaceuticals Inc |
| PLRX - Pliant Therapeutics Inc | HOLD | 0 @ USD 1.53999 | USD 0 | The current share valuation price of PLRX based on adjusted close was USD 1.53999. The average price that PLRX shares were previous bought at was USD 1.5097. The current market price is 2.0% higher than average price they were purchased at. The value of the holding in PLRX has increased by USD 2,029 compared to the previous valuation of Pliant Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PRAX - Praxis Precision Medicines Inc | HOLD | 0 @ USD 186.15 | USD 0 | The current share valuation price of PRAX based on adjusted close was USD 186.15. The average price that PRAX shares were previous bought at was USD 82.309. The current market price is 126.2% higher than average price they were purchased at. The value of the holding in PRAX has increased by USD 104,033 compared to the previous valuation of Praxis Precision Medicines Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PRME - Prime Medicine, Inc. Common Stock | HOLD | 0 @ USD 3.61 | USD 0 | The current share valuation price of PRME based on adjusted close was USD 3.61. The average price that PRME shares were previous bought at was USD 3.86742. The current market price is -6.7% lower than average price they were purchased at. The value of the holding in PRME has increased by USD 37,731 compared to the previous valuation of Prime Medicine, Inc. Common Stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PRTA - Prothena Corporation plc | HOLD | 0 @ USD 11.17 | USD 0 | The current share valuation price of PRTA based on adjusted close was USD 11.17. The average price that PRTA shares were previous bought at was USD 9.31686. The current market price is 19.9% higher than average price they were purchased at. The value of the holding in PRTA has increased by USD 31,372 compared to the previous valuation of Prothena Corporation plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PTCT - PTC Therapeutics Inc | HOLD | 0 @ USD 75.76 | USD 0 | The current share valuation price of PTCT based on adjusted close was USD 75.76. The average price that PTCT shares were previous bought at was USD 59.1555. The current market price is 28.1% higher than average price they were purchased at. The value of the holding in PTCT has fallen by USD 152,383 compared to the previous valuation of PTC Therapeutics Inc |
| PTGX - Protagonist Therapeutics Inc | HOLD | 0 @ USD 86.07 | USD 0 | The current share valuation price of PTGX based on adjusted close was USD 86.07. The average price that PTGX shares were previous bought at was USD 61.6824. The current market price is 39.5% higher than average price they were purchased at. The value of the holding in PTGX has increased by USD 62,131 compared to the previous valuation of Protagonist Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| QURE - Uniqure NV | HOLD | 0 @ USD 25.48 | USD 0 | The current share valuation price of QURE based on adjusted close was USD 25.48. The average price that QURE shares were previous bought at was USD 23.7827. The current market price is 7.1% higher than average price they were purchased at. The value of the holding in QURE has increased by USD 6,147 compared to the previous valuation of Uniqure NV however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RARE - Ultragenyx | HOLD | 0 @ USD 36.45 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 36.45. The average price that RARE shares were previous bought at was USD 35.9216. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in RARE has increased by USD 203,119 compared to the previous valuation of Ultragenyx however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RARE - WISETFWTMRARETFP | HOLD | 0 @ USD 36.45 | USD 0 | The current share valuation price of RARE based on adjusted close was USD 36.45. The average price that RARE shares were previous bought at was USD 35.9216. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in RARE has increased by USD 203,119 compared to the previous valuation of WISETFWTMRARETFP however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RCKT - Rocket Pharmaceuticals Inc | HOLD | 0 @ USD 3.34 | USD 0 | The current share valuation price of RCKT based on adjusted close was USD 3.34. The average price that RCKT shares were previous bought at was USD 4.82775. The current market price is -30.8% lower than average price they were purchased at. The value of the holding in RCKT has increased by USD 18,629 compared to the previous valuation of Rocket Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| REPL - Replimune Group Inc | HOLD | 0 @ USD 10.32 | USD 0 | The current share valuation price of REPL based on adjusted close was USD 10.32. The average price that REPL shares were previous bought at was USD 9.05758. The current market price is 13.9% higher than average price they were purchased at. The value of the holding in REPL has increased by USD 17,807 compared to the previous valuation of Replimune Group Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RGNX - Regenxbio Inc | HOLD | 0 @ USD 12.88 | USD 0 | The current share valuation price of RGNX based on adjusted close was USD 12.88. The average price that RGNX shares were previous bought at was USD 9.70339. The current market price is 32.7% higher than average price they were purchased at. The value of the holding in RGNX has increased by USD 24,496 compared to the previous valuation of Regenxbio Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RLAY - Relay Therapeutics Inc | HOLD | 0 @ USD 7.83 | USD 0 | The current share valuation price of RLAY based on adjusted close was USD 7.83. The average price that RLAY shares were previous bought at was USD 4.61623. The current market price is 69.6% higher than average price they were purchased at. The value of the holding in RLAY has increased by USD 40,795 compared to the previous valuation of Relay Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RVMD - Revolution Medicines Inc | HOLD | 0 @ USD 77.69 | USD 0 | The current share valuation price of RVMD based on adjusted close was USD 77.69. The average price that RVMD shares were previous bought at was USD 46.7356. The current market price is 66.2% higher than average price they were purchased at. The value of the holding in RVMD has increased by USD 312,970 compared to the previous valuation of Revolution Medicines Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RXRX - Recursion Pharmaceuticals Inc | HOLD | 0 @ USD 4.66 | USD 0 | The current share valuation price of RXRX based on adjusted close was USD 4.66. The average price that RXRX shares were previous bought at was USD 5.56598. The current market price is -16.3% lower than average price they were purchased at. The value of the holding in RXRX has increased by USD 102,764 compared to the previous valuation of Recursion Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RYTM - Rhythm Pharmaceuticals Inc | HOLD | 0 @ USD 104.63 | USD 0 | The current share valuation price of RYTM based on adjusted close was USD 104.63. The average price that RYTM shares were previous bought at was USD 80.3852. The current market price is 30.2% higher than average price they were purchased at. The value of the holding in RYTM has increased by USD 151,405 compared to the previous valuation of Rhythm Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SANA - Sana Biotechnology Inc | HOLD | 0 @ USD 4.47 | USD 0 | The current share valuation price of SANA based on adjusted close was USD 4.47. The average price that SANA shares were previous bought at was USD 3.27616. The current market price is 36.4% higher than average price they were purchased at. The value of the holding in SANA has increased by USD 91,389 compared to the previous valuation of Sana Biotechnology Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SIGA - SIGA Technologies Inc | HOLD | 0 @ USD 6.23999 | USD 0 | The current share valuation price of SIGA based on adjusted close was USD 6.23999. The average price that SIGA shares were previous bought at was USD 6.66314. The current market price is -6.4% lower than average price they were purchased at. The value of the holding in SIGA has increased by USD 15,203 compared to the previous valuation of SIGA Technologies Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SMMT - Summit Therapeutics PLC | HOLD | 0 @ USD 18.37 | USD 0 | The current share valuation price of SMMT based on adjusted close was USD 18.37. The average price that SMMT shares were previous bought at was USD 20.5771. The current market price is -10.7% lower than average price they were purchased at. The value of the holding in SMMT has increased by USD 584,437 compared to the previous valuation of Summit Therapeutics PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SNDX - Syndax Pharmaceuticals Inc | HOLD | 0 @ USD 19.71 | USD 0 | The current share valuation price of SNDX based on adjusted close was USD 19.71. The average price that SNDX shares were previous bought at was USD 12.9237. The current market price is 52.5% higher than average price they were purchased at. The value of the holding in SNDX has increased by USD 55,104 compared to the previous valuation of Syndax Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SNY - Sanofi ADR | HOLD | 0 @ USD 49.69 | USD 0 | The current share valuation price of SNY based on adjusted close was USD 49.69. The average price that SNY shares were previous bought at was USD 50.0613. The current market price is -0.7% lower than average price they were purchased at. The value of the holding in SNY has fallen by USD 30,164 compared to the previous valuation of Sanofi ADR |
| SPRY - Silverback Therapeutics Inc | HOLD | 0 @ USD 9.55 | USD 0 | The current share valuation price of SPRY based on adjusted close was USD 9.55. The average price that SPRY shares were previous bought at was USD 12.7372. The current market price is -25.0% lower than average price they were purchased at. The value of the holding in SPRY has increased by USD 34,692 compared to the previous valuation of Silverback Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SRPT - Sarepta Therapeutics Inc | HOLD | 0 @ USD 21.84 | USD 0 | The current share valuation price of SRPT based on adjusted close was USD 21.84. The average price that SRPT shares were previous bought at was USD 31.7733. The current market price is -31.3% lower than average price they were purchased at. The value of the holding in SRPT has increased by USD 92,978 compared to the previous valuation of Sarepta Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SRRK - Scholar Rock Holding Corp | HOLD | 0 @ USD 43.51 | USD 0 | The current share valuation price of SRRK based on adjusted close was USD 43.51. The average price that SRRK shares were previous bought at was USD 35.914. The current market price is 21.2% higher than average price they were purchased at. The value of the holding in SRRK has increased by USD 164,460 compared to the previous valuation of Scholar Rock Holding Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| STOK - Stoke Therapeutics Inc | HOLD | 0 @ USD 30.96 | USD 0 | The current share valuation price of STOK based on adjusted close was USD 30.96. The average price that STOK shares were previous bought at was USD 18.3679. The current market price is 68.6% higher than average price they were purchased at. The value of the holding in STOK has increased by USD 44,703 compared to the previous valuation of Stoke Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SUPN - Supernus Pharmaceuticals Inc | HOLD | 0 @ USD 44.76 | USD 0 | The current share valuation price of SUPN based on adjusted close was USD 44.76. The average price that SUPN shares were previous bought at was USD 38.909. The current market price is 15.0% higher than average price they were purchased at. The value of the holding in SUPN has increased by USD 25,412 compared to the previous valuation of Supernus Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SVRA - Savara Inc | HOLD | 0 @ USD 6.3 | USD 0 | The current share valuation price of SVRA based on adjusted close was USD 6.3. The average price that SVRA shares were previous bought at was USD 3.33863. The current market price is 88.7% higher than average price they were purchased at. The value of the holding in SVRA has increased by USD 58,677 compared to the previous valuation of Savara Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SYRE - Spyre Therapeutics Inc. | HOLD | 0 @ USD 32.2 | USD 0 | The current share valuation price of SYRE based on adjusted close was USD 32.2. The average price that SYRE shares were previous bought at was USD 19.2365. The current market price is 67.4% higher than average price they were purchased at. The value of the holding in SYRE has increased by USD 158,688 compared to the previous valuation of Spyre Therapeutics Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TARS - Tarsus Pharmaceuticals Inc | HOLD | 0 @ USD 81.88 | USD 0 | The current share valuation price of TARS based on adjusted close was USD 81.88. The average price that TARS shares were previous bought at was USD 54.1489. The current market price is 51.2% higher than average price they were purchased at. The value of the holding in TARS has increased by USD 72,831 compared to the previous valuation of Tarsus Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TBPH - Theravance Biopharma Inc | HOLD | 0 @ USD 18.89 | USD 0 | The current share valuation price of TBPH based on adjusted close was USD 18.89. The average price that TBPH shares were previous bought at was USD 12.9798. The current market price is 45.5% higher than average price they were purchased at. The value of the holding in TBPH has increased by USD 16,122 compared to the previous valuation of Theravance Biopharma Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TERN - Tern Plc | HOLD | 0 @ USD 27.49 | USD 0 | The current share valuation price of TERN based on adjusted close was USD 27.49. The average price that TERN shares were previous bought at was USD 8.53832. The current market price is 222.0% higher than average price they were purchased at. The value of the holding in TERN has increased by USD 103,515 compared to the previous valuation of Tern Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TNGX - Tango Therapeutics Inc | HOLD | 0 @ USD 9.57001 | USD 0 | The current share valuation price of TNGX based on adjusted close was USD 9.57001. The average price that TNGX shares were previous bought at was USD 6.92927. The current market price is 38.1% higher than average price they were purchased at. The value of the holding in TNGX has fallen by USD 39,437 compared to the previous valuation of Tango Therapeutics Inc |
| TRDA - Entrada Therapeutics Inc | HOLD | 0 @ USD 10.07 | USD 0 | The current share valuation price of TRDA based on adjusted close was USD 10.07. The average price that TRDA shares were previous bought at was USD 8.01501. The current market price is 25.6% higher than average price they were purchased at. The value of the holding in TRDA has increased by USD 6,279 compared to the previous valuation of Entrada Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TSHA - Taysha Gene Therapies Inc | HOLD | 0 @ USD 4.49 | USD 0 | The current share valuation price of TSHA based on adjusted close was USD 4.49. The average price that TSHA shares were previous bought at was USD 3.08241. The current market price is 45.7% higher than average price they were purchased at. The value of the holding in TSHA has increased by USD 81,632 compared to the previous valuation of Taysha Gene Therapies Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TVTX - Travere Therapeutics Inc | HOLD | 0 @ USD 34.85 | USD 0 | The current share valuation price of TVTX based on adjusted close was USD 34.85. The average price that TVTX shares were previous bought at was USD 22.4652. The current market price is 55.1% higher than average price they were purchased at. The value of the holding in TVTX has increased by USD 53,234 compared to the previous valuation of Travere Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TWST - Twist Bioscience Corp | HOLD | 0 @ USD 31.17 | USD 0 | The current share valuation price of TWST based on adjusted close was USD 31.17. The average price that TWST shares were previous bought at was USD 35.0568. The current market price is -11.1% lower than average price they were purchased at. The value of the holding in TWST has increased by USD 61,661 compared to the previous valuation of Twist Bioscience Corp however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TXG - 10X Genomics Inc | HOLD | 0 @ USD 17.87 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 17.87. The average price that TXG shares were previous bought at was USD 13.071. The current market price is 36.7% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 5,625 compared to the previous valuation of 10X Genomics Inc |
| TXG - Terex Corporation | HOLD | 0 @ USD 17.87 | USD 0 | The current share valuation price of TXG based on adjusted close was USD 17.87. The average price that TXG shares were previous bought at was USD 13.071. The current market price is 36.7% higher than average price they were purchased at. The value of the holding in TXG has fallen by USD 5,625 compared to the previous valuation of Terex Corporation |
| URGN - UroGen Pharma Ltd | HOLD | 0 @ USD 24.35 | USD 0 | The current share valuation price of URGN based on adjusted close was USD 24.35. The average price that URGN shares were previous bought at was USD 16.2618. The current market price is 49.7% higher than average price they were purchased at. The value of the holding in URGN has fallen by USD 1,000 compared to the previous valuation of UroGen Pharma Ltd |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 480.96 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 480.96. The average price that UTHR shares were previous bought at was USD 367.829. The current market price is 30.8% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 216,419 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VCEL - Vericel Corp Ord | HOLD | 0 @ USD 37.39 | USD 0 | The current share valuation price of VCEL based on adjusted close was USD 37.39. The average price that VCEL shares were previous bought at was USD 40.5058. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in VCEL has fallen by USD 9,111 compared to the previous valuation of Vericel Corp Ord |
| VCYT - Veracyte Inc | HOLD | 0 @ USD 47.75 | USD 0 | The current share valuation price of VCYT based on adjusted close was USD 47.75. The average price that VCYT shares were previous bought at was USD 33.7248. The current market price is 41.6% higher than average price they were purchased at. The value of the holding in VCYT has increased by USD 88,614 compared to the previous valuation of Veracyte Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VERA - Vera Therapeutics Inc | HOLD | 0 @ USD 41.26 | USD 0 | The current share valuation price of VERA based on adjusted close was USD 41.26. The average price that VERA shares were previous bought at was USD 28.0075. The current market price is 47.3% higher than average price they were purchased at. The value of the holding in VERA has increased by USD 177,731 compared to the previous valuation of Vera Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VIR - Vir Biotechnology Inc | HOLD | 0 @ USD 6.27 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.27. The average price that VIR shares were previous bought at was USD 5.83673. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 61,440 compared to the previous valuation of Vir Biotechnology Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VIR - Vidrala S.A | HOLD | 0 @ USD 6.27 | USD 0 | The current share valuation price of VIR based on adjusted close was USD 6.27. The average price that VIR shares were previous bought at was USD 5.83673. The current market price is 7.4% higher than average price they were purchased at. The value of the holding in VIR has increased by USD 61,440 compared to the previous valuation of Vidrala S.A however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VNDA - Vanda Pharmaceuticals Inc | HOLD | 0 @ USD 5.27 | USD 0 | The current share valuation price of VNDA based on adjusted close was USD 5.27. The average price that VNDA shares were previous bought at was USD 4.87361. The current market price is 8.1% higher than average price they were purchased at. The value of the holding in VNDA has increased by USD 15,633 compared to the previous valuation of Vanda Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VTRS - Viatris Inc | HOLD | 0 @ USD 10.84 | USD 0 | The current share valuation price of VTRS based on adjusted close was USD 10.84. The average price that VTRS shares were previous bought at was USD 9.78952. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in VTRS has increased by USD 106,555 compared to the previous valuation of Viatris Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VYGR - Voyager Therapeutics Inc | HOLD | 0 @ USD 4.22999 | USD 0 | The current share valuation price of VYGR based on adjusted close was USD 4.22999. The average price that VYGR shares were previous bought at was USD 3.88405. The current market price is 8.9% higher than average price they were purchased at. The value of the holding in VYGR has increased by USD 16,516 compared to the previous valuation of Voyager Therapeutics Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| WVE - Wave Life Sciences Ltd | HOLD | 0 @ USD 7.14 | USD 0 | The current share valuation price of WVE based on adjusted close was USD 7.14. The average price that WVE shares were previous bought at was USD 8.24476. The current market price is -13.4% lower than average price they were purchased at. The value of the holding in WVE has increased by USD 17,017 compared to the previous valuation of Wave Life Sciences Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| XENE - Xenon Pharmaceuticals Inc | HOLD | 0 @ USD 44.29 | USD 0 | The current share valuation price of XENE based on adjusted close was USD 44.29. The average price that XENE shares were previous bought at was USD 36.8888. The current market price is 20.1% higher than average price they were purchased at. The value of the holding in XENE has increased by USD 76,801 compared to the previous valuation of Xenon Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| XERS - Xeris Pharmaceuticals Inc | HOLD | 0 @ USD 6.73 | USD 0 | The current share valuation price of XERS based on adjusted close was USD 6.73. The average price that XERS shares were previous bought at was USD 6.19417. The current market price is 8.7% higher than average price they were purchased at. The value of the holding in XERS has increased by USD 30,086 compared to the previous valuation of Xeris Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| XNCR - Xencor Inc | HOLD | 0 @ USD 17.31 | USD 0 | The current share valuation price of XNCR based on adjusted close was USD 17.31. The average price that XNCR shares were previous bought at was USD 12.0233. The current market price is 44.0% higher than average price they were purchased at. The value of the holding in XNCR has increased by USD 65,488 compared to the previous valuation of Xencor Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ZLAB - Zai Lab Ltd | HOLD | 0 @ USD 19.75 | USD 0 | The current share valuation price of ZLAB based on adjusted close was USD 19.75. The average price that ZLAB shares were previous bought at was USD 32.0387. The current market price is -38.4% lower than average price they were purchased at. The value of the holding in ZLAB has increased by USD 7,649 compared to the previous valuation of Zai Lab Ltd however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ZYME - Zymeworks Inc. Common Stock | HOLD | 0 @ USD 26.22 | USD 0 | The current share valuation price of ZYME based on adjusted close was USD 26.22. The average price that ZYME shares were previous bought at was USD 16.2988. The current market price is 60.9% higher than average price they were purchased at. The value of the holding in ZYME has increased by USD 60,229 compared to the previous valuation of Zymeworks Inc. Common Stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| STRO - Sutro Biopharma | SELL | -47,700 @ USD 8.7 | USD -414,990 | The ETF sold 47700 shares of STRO on 2025-12-03. The shares were previously bought for an average price of USD 0.899783. The Sutro Biopharma shares were sold for 866.9% higher than average price of previous purchases. This sale made a profit of USD 372,070 The average price that the ETF previously sold STRO share for is USD 0.847108 so the ETF has sold 47700 shares on 2025-12-03 at a higher price than the previous selling average. |